©Reuters.
Alphatec Holdings , Inc. (NASDAQ:) is a surgical and medical device company in which one of its directors recently purchased stock. Evan Bakst, a director of Alphatec, will acquire 15,000 shares of common stock at his weighted average price per share of $13.53, bringing his total investment to $202,950.
The trade took place on March 14, 2024, and was executed in multiple trades at prices ranging from $13.50 to $13.55. The acquisition increases Baxt's direct ownership in the company, bringing the total number of Alphatec common shares to 1,089,038.
Shareholders and potential investors often pay close attention to insider transactions because they can glean insight into how a company's management views its stock's value and prospects. The recent acquisition by Bakst may be interpreted as a sign of confidence in Alphatec Holdings' future.
Alphatec Holdings, Inc. is incorporated in Delaware and has a business address in Carlsbad, California. The company continues to focus on developing and marketing products for the surgical and medical device sectors.
Investors interested in transaction details can request more detailed information about the number of shares purchased at individual prices within the reported range.
Investment Pro Insights
As investors digest the news of Director Evan Bakst's recent purchase of Alphatec Holdings (NASDAQ:ATEC) stock, it's important to note the broader financial picture provided by InvestingPro. The company's market capitalization is $1.86 billion, reflecting its size and market value in the surgical and medical device space. Despite strong revenue growth of 37.45% over the past twelve months as of Q4 2023, Alphatec's performance metrics suggest some challenges. In particular, the company is currently trading at a high price/book value of 23.77 times, which may indicate that the stock is quite expensive compared to the company's book value.
From a profitability perspective, Alphatec has not made a profit in the past 12 months, with an adjusted P/E ratio of -11.25, indicating that the company is operating at a loss. This is in line with InvestingPro's tip that analysts don't expect the company to turn a profit this year. Furthermore, the stock price has been highly volatile, with a one-month total stock return of -15.66%. This can be an important consideration for investors looking for stable returns.
However, there are also positive signals. Alphatech's current assets exceed short-term debt, suggesting that the company has a strong liquidity position to meet its immediate financial needs. This is an encouraging sign for investors concerned about the company's financial health in the short term.
To better understand Alphatec's financial health and future prospects, investors can explore additional InvestingPro Tips. Nine more tips are now available and can be accessed by visiting InvestingPro.Use coupon code pro news 24 Get an extra 10% off annual or biennial Pro and Pro+ subscriptions, and get even more insights to guide your investment decisions.
This article was generated with the help of AI and reviewed by an editor. Please see our Terms of Use for more information.
